The growing popularity of medications like Ozempic and Wegovy, initially prescribed for type 2 diabetes and obesity, has extended to their observed cardiovascular benefits. However, a latest study published in BMJ Medicine reveals a concerning trend: these heart-health advantages appear to diminish and cardiovascular risk may even increase, when individuals discontinue use. The findings underscore a critical point often overlooked in the enthusiasm surrounding these drugs – their effects aren’t simply reversed when stopped, but may actively contribute to increased risk within a relatively short timeframe.
Researchers found that even a six-month break from GLP-1 receptor agonists (GLP-1s) can begin to erode the protective effects against heart attack, and stroke. This challenges the perception of these medications as a “quick fix” and suggests they may need to be considered as a long-term treatment strategy for those seeking to reduce cardiovascular risk. The study’s lead author, Dr. Ziyad Al-Aly of Washington University School of Medicine, emphasized in a press release, “There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.”
The Study: Veterans and Cardiovascular Outcomes
The research team analyzed data from 333,687 veterans, comparing 132,551 individuals prescribed a GLP-1 medication for type 2 diabetes with 201,136 who were prescribed sulfonylureas, another common diabetes medication. Participants were followed for up to three years. The study meticulously tracked GLP-1 treatment status every six months, categorizing individuals based on continuous use, interruption followed by resumption, and complete discontinuation. This allowed researchers to assess the impact of varying durations of GLP-1 use and breaks in treatment on cardiovascular events.
The findings revealed a clear correlation between consistent GLP-1 use and reduced cardiovascular risk. Participants who continuously used GLP-1s over the three-year study period experienced an 18% reduction in major cardiovascular events compared to those taking sulfonylureas. Even periods of prior use offered some continued protection; those who had taken GLP-1s for 2 or 2.5 years before stopping still saw a 7% and 15% reduction in risk, respectively. However, the benefits began to wane quickly. A mere six-month interruption in GLP-1 use before resuming treatment led to a 4% to 8% increase in risk compared to continuous use, and discontinuing use for one to two years without resuming resulted in a 14% to 22% increased risk.
How GLP-1s Impact Heart Health
The cardiovascular benefits of GLP-1s aren’t solely attributable to weight loss, explains Dr. Robert Glatter, an attending physician in the Department of Emergency Medicine at Lenox Hill Hospital in New York City, who was not involved in the study. “GLP-1 drugs likely help cardiovascular health through several pathways at once, not just by lowering weight,” he said. These medications improve blood sugar control, modestly lower blood pressure, and may enhance lipid and vascular function. Crucially, they also appear to reduce inflammation and the growth of atherosclerotic plaque – the buildup of fats, cholesterol, and other substances in artery walls – which are key drivers of heart attacks and strokes.
Some research suggests GLP-1s may even have direct protective effects on the heart and blood vessels, independent of weight loss. This is significant because chronic inflammation is increasingly recognized as a central factor in the development of cardiovascular disease. By addressing this underlying inflammatory process, GLP-1s may offer a more comprehensive approach to heart health.
Practical Implications and Considerations
The study’s findings have important implications for both patients and healthcare providers. For individuals currently taking GLP-1s, particularly those prescribed them for weight loss, it’s crucial to understand that discontinuing the medication may not simply return them to their pre-treatment state. The potential for increased cardiovascular risk needs to be carefully considered.
“When patients use GLP-1 medications primarily for weight loss, I caution them that it is extremely easy to regain the weight when these medications are discontinued and subsequently lose the health benefits gained from achieving a healthy weight,” says Dr. Mir Ali, a bariatric surgeon and medical director at MemorialCare Surgical Weight Loss Center in Fountain Valley, California, who was not involved in the study.
Abruptly stopping a GLP-1 medication, such as semaglutide (Ozempic, Wegovy), can also lead to withdrawal symptoms, including nausea, increased appetite, weight regain, and even changes in blood pressure. A gradual tapering off of the medication, under the guidance of a healthcare professional, may help minimize these effects. Maintaining healthy lifestyle habits – a balanced diet and regular physical activity – is also essential when considering discontinuing GLP-1s.
The researchers emphasize that GLP-1 therapy appears to function more like a long-term risk-reduction strategy than a short-term intervention. As Dr. Al-Aly notes, the benefits accumulated through treatment can be lost surprisingly quickly when interrupted, highlighting the importance of persistence and ongoing medical follow-up.
If you are considering stopping a GLP-1 medication, a thorough discussion with your doctor is paramount. They can help you weigh the potential risks and benefits, develop a personalized plan, and monitor your health closely.
Disclaimer: This article provides informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment or care.
Looking ahead, further research is needed to fully understand the long-term effects of GLP-1 discontinuation and to identify strategies for mitigating the increased cardiovascular risk. The FDA continues to monitor the safety and efficacy of these medications, and updates will be provided as they become available. Share your thoughts on this evolving area of medicine in the comments below.
